US2023330200A1PendingUtilityA1

Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer

61
Assignee: ASTELLAS PHARMA INCPriority: Dec 2, 2019Filed: May 15, 2023Published: Oct 19, 2023
Est. expiryDec 2, 2039(~13.3 yrs left)· nominal 20-yr term from priority
Inventors:Ayaka AkibaTatsuya OkudairaYasuhide MasuharaKeisuke OhsumiShinichiro Fujii
A61K 39/00A61K 35/15A61K 2039/5156A61K 39/001188A61P 35/00A61K 45/06C07K 14/705C07K 14/70539C12N 5/0686C12N 5/10C12N 2510/00C12N 15/85A61K 35/22A61P 37/04A61P 43/00C07K 14/4748A61K 39/39C07K 14/70596C12N 2510/02
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A cell, comprising:
 a polynucleotide encoding human CD1d and a polynucleotide encoding human NY-ESO-1 or a fragment thereof,   wherein the polynucleotide encoding human NY-ESO-1 or a fragment thereof is operably linked to a drug inducible promoter,   wherein the cell is cultured in vitro in the presence of a drug to express human CD1d and human NY-ESO-1 or a fragment thereof   wherein the cell expresses human NY-ESO-1 or a fragment thereof at an expression level of 245 ng to 45000 ng per 10 6  cells,   wherein a CD1d ligand is loaded on the surface of the cell,   wherein the CD1d ligand is α-GalCer, and   wherein the cell is derived from a human embryonic kidney cell.   
     
     
         2 . The cell according to  claim 1 , wherein the drug inducible promoter is a tetracycline inducible promoter. 
     
     
         3 . The cell according to  claim 2 , wherein the tetracycline inducible promoter is a TRE3G promoter. 
     
     
         4 . The cell according to  claim 1 , wherein the cell is cultured in the presence of a tetracycline. 
     
     
         5 . The cell according to  claim 2 , wherein the cell is cultured in the presence of a tetracycline. 
     
     
         6 . The cell according to  claim 1 , wherein the human embryonic kidney cell is a human embryonic kidney cell 293 (HEK293) cell. 
     
     
         7 . A pharmaceutical composition comprising a cell according to  claim 1 . 
     
     
         8 . A pharmaceutical composition comprising a cell according to  claim 2 . 
     
     
         9 . A method for producing a cell according to  claim 1 , comprising culturing the cell in the presence of a drug, thereby inducing the expression of human NY-ESO-1 or a fragment thereof. 
     
     
         10 . The method according to  claim 9 , further comprising loading α-GalCer onto the surface of the cell. 
     
     
         11 . The method according to  claim 9 , wherein the drug inducible promoter is a tetracycline inducible promoter. 
     
     
         12 . The method according to  claim 11 , wherein the cell is cultured in the presence of a tetracycline. 
     
     
         13 . The method according to  claim 9 , wherein the human embryonic kidney cell is a human embryonic kidney cell 293 (HEK293) cell. 
     
     
         14 . A method for producing a cell, comprising:
 introducing a polynucleotide encoding human CD1d and a polynucleotide encoding human NY-ESO-1 or a fragment thereof to a cell derived from a human embryonic kidney cell, wherein the polynucleotide encoding human NY-ESO-1 or a fragment thereof is operably linked to drug inducible promoter; or   introducing a polynucleotide encoding human NY-ESO-1 or a fragment thereof to a cell derived from a human embryonic kidney cell endogenously expressing human CD1d, wherein the polynucleotide encoding human NY-ESO-1 or a fragment thereof is operably linked to a drug inducible promoter.   
     
     
         15 . The method according to  claim 14 , further comprising culturing the cell obtained in the presence of drug, thereby inducing the expression of human NY-ESO-1 or a fragment thereof. 
     
     
         16 . The method according to  claim 15 , further comprising loading α-GalCer onto the surface of the cell. 
     
     
         17 . The method according to  claim 14 , wherein the drug inducible promoter is a tetracycline inducible promoter. 
     
     
         18 . The method according to  claim 17 , wherein the cell is cultured in the presence of a tetracycline. 
     
     
         19 . The method according to  claim 14 , wherein the human embryonic kidney cell is a human embryonic kidney cell 293 (HEK293) cell.

Join the waitlist — get patent alerts

Track US2023330200A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.